Gastrointestinal Cancer

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

VS-7375 earned FDA fast track designation for KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extrapancreatic neuroendocrine tumors.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.

Panelists discuss how newer clinical trials such as PEAK and INSIGHT are investigating combination therapies and mutation-specific treatment approaches to overcome secondary resistance mutations, while also exploring pan-KIT inhibitors and senescence-targeting strategies to improve outcomes.

Panelists discuss how most gastrointestinal stromal tumor (GIST) patients can tolerate approved agents with proper adverse effect management, the efficacy data from the INVICTUS and INTRIGUE trials that led to ripretinib's approval, and the unique adverse effects such as alopecia that distinguish ripretinib from other therapies.

Drs Armstrong and Tawagi discussed key data from the phase 3 MATTERHORN trial, which were presented at the 2025 ASCO Annual Meeting.

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

The FDA has approved SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.